Royalty Pharma earnings were $770.9M for the trailing 12 months ending Dec 31, 2025, with -6.8% growth year over year. The latest RPRX earnings report on Dec 31, 2025 announced Q4 2025 earnings of $214.2M, down 25.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RPRX reported annual earnings of $770.9M, with -10.2% growth.
RPRX past earnings growth
How has RPRX's earnings growth performed historically?
On RPRX's earnings call on Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q4 2025 earnings per share (EPS) of $0.50, up 6.38% year over year. Total RPRX earnings for the quarter were $214.21 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $0.47.
As of the last Royalty Pharma earnings report, Royalty Pharma is currently profitable. Royalty Pharma's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $770.95 million, a 10.25% decrease year over year.
What was RPRX's earnings growth in the past year?
As of Royalty Pharma's earnings date in Invalid Date, Royalty Pharma's earnings has grown -6.77% year over year. This is 78.14 percentage points lower than the US Biotechnology industry earnings growth rate of 71.37%. RPRX earnings in the past year totalled $770.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.